EP1858551A2 - Kombinationsvakzine mit ganzzelligem keuchhusten-antigen - Google Patents

Kombinationsvakzine mit ganzzelligem keuchhusten-antigen

Info

Publication number
EP1858551A2
EP1858551A2 EP06727568A EP06727568A EP1858551A2 EP 1858551 A2 EP1858551 A2 EP 1858551A2 EP 06727568 A EP06727568 A EP 06727568A EP 06727568 A EP06727568 A EP 06727568A EP 1858551 A2 EP1858551 A2 EP 1858551A2
Authority
EP
European Patent Office
Prior art keywords
vaccine
component
conjugate
capsular saccharide
hbsag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06727568A
Other languages
English (en)
French (fr)
Other versions
EP1858551B1 (de
Inventor
Mario Chiron Vaccines CONTORNI
Donatella Mannucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34531441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1858551(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Priority to EP10075177A priority Critical patent/EP2206515A1/de
Publication of EP1858551A2 publication Critical patent/EP1858551A2/de
Application granted granted Critical
Publication of EP1858551B1 publication Critical patent/EP1858551B1/de
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • This invention is in the field of combination vaccines, that is vaccines containing a mixture of immunogens from more than one pathogen, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen.
  • Combination vaccines offer patients the advantage of receiving a reduced number of injections, which leads to the clinical advantage of increased compliance (e.g. see chapter 29 of reference 1).
  • Six pathogens of particular concern, particularly in children, are Corynebacterium diphtheriae (the cause of diphtheria), Clostridium tetani (the cause of tetanus/lockjaw), Bordetella pertussis (whooping cough), hepatitis B virus ('HepB', viral hepatitis), Haemophilus influenzae type b ('Hib', a cause of bacterial meningitis and pneumonia) and Neisseria meningitidis (meningococcal meningitis and septicaemia).
  • Vaccines against each of these pathogens are known, and a pentavalent vaccine including all five of the 'D', 'T', 'P', 'HepB', and 'Hib' components for simultaneous combined administration is marketed by GlaxoSmithKline under the name TRITANRIX-HepB/Hib.
  • the 'P' component in this pentavalent vaccine is based on whole cell pertussis ('Pw') antigen.
  • the DTP and HepB components of this vaccine are in a combined solution within a vial (and this tetravalent DTPw-HepB combination is sold separately as the 'TRITANRIX-HepB' product), but the Hib component is freeze-dried and contained in a separate vial.
  • the DTPw-HepB solution is used to reconstitute the Hib component at the time of use, extemporaneously forming the pentavalent vaccine in the vial.
  • TRITANRIX-HepB/Hib does not protect against meningococcal infection.
  • Example 3 of reference 2 discloses the results of human clinical trials in which the tetravalent TRITANRIX-HepB product was extemporaneously mixed with conjugated capsular saccharides from Hib and from serogroups A and C of meningococcus ('MenA' and 'MenC'). The authors report that this heptavalent mixture induced a good immune response against each antigen and was well tolerated by infants. Full details of the Hib, MenA and MenC components are not given. Similar information is reported in references 3 and 4.
  • the invention is based on studies of vaccine that comprise D-T-Pw-HepB-Hib antigens (as in the TRITANRIX-HepB/Hib product) and also comprise one or more meningococcal conjugate antigens. A number of improvements and variations of these vaccines have been discovered, and these are the topic of the invention.
  • Vaccines of the invention comprise:
  • the meningococcal saccharide(s) can be from one or more of serogroups A, C, W135 and Y. Common nomenclature refers to these four serogroups as 'MenA', 'MenC, 'MenW135' and 'MenY'. Conjugate antigens are generally referred to herein as 'MenA-X' etc., where 'X' represents the conjugate's carrier protein. Conjugates with specific carrier proteins are then referred to as 'MenA-CRM' or 'MenC-D', etc.
  • Preferred vaccines contain meningococcal conjugates for at least serogroup C, and preferably for both serogroup A and C.
  • preferred vaccines are hexavalent (D-T-Pw-HB sAg-Hib-MenC) or heptavalent (D-T-Pw-HBsAg-Hib-MenA-MenC).
  • Vaccines of the invention can be prepared in liquid fo ⁇ nat (i.e. where all antigens are in aqueous solution or suspension) during manufacture, or they can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising Hib and meningococcal conjugates.
  • the two components are preferably in separate containers (e.g.
  • kits comprising components (a) and (b).
  • the contents of the first container are preferably aqueous, and the contents of the second container are preferably lyophilised, such that vaccines of the invention can be prepared by reconstituting the lyophilised component with the aqueous D-T-wP-HBsAg component.
  • Weight ratio of the Hib conjugate Hib conjugates are well known, but they come in various forms. For instance, Table 14-7 of reference 1 gives the characteristics of four different Hib conjugates. This table reports that the saccharide xarrier weight ratio varies between 1.4:1 in 'PRP-D' (excess saccharide) to 0.06:1 in 'PRP-OMP' (excess protein). All of these conjugates have been used in combination vaccines, but one aspect of the invention has selected a specific weight ratio range for use in combination vaccines that include meningococcal conjugates.
  • a Hib conjugate should have a saccharide xarrier weight ratio of between 1:0.3 and 1 :2.
  • the weight ratio of saccharide to carrier can be beyond this range, and is between the range of 1:2 and 1:4.
  • Hib conjugates in this range show excellent immunogenicity when combined with meningococcal conjugates in combination pediatric vaccines and do not duffer from any immune interference, even though the carrier protein is also present as free antigen (e.g. where the carrier protein is tetanus toxoid or diphtheria toxoid).
  • the extra carrier protein can contribute to immunity e.g. against tetanus or diphtheria.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) a cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the H.influen ⁇ ae conjugate has a weight excess of carrier to saccharide, wherein the weight ratio of carrier to saccharide is between 2:1 and 4:1.
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) cellular pertussis antigen ('Pw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg component; (b) combining the H.influenzae and N.
  • meningitidis conjugates to give a mixed conjugate component, wherein the H.influenzae conjugate has a weight excess of carrier to saccharide with a weight ratio of carrier to saccharide of between 2:1 and 4:1; and (c) mixing the D-T-Pw-HBsAg component with the conjugate component, to give the combination vaccine.
  • the Hib conjugate has a weight excess of carrier protein.
  • the weight ratio is between 2:1 and 4:1, and is preferably between 2.5:1 and 3.5:1.
  • a weight ratio between 2.8:1 and 3.2:1 can be used, and a weight ratio of about 3:1 is preferred.
  • a composition of the invention will include between 20-40 ⁇ g of carrier, preferably about 30 ⁇ g. This ratio is in direct contrast to the teaching of reference 5.
  • the carrier protein for the Hib conjugate is preferably a tetanus toxoid, and so, for lO ⁇ g of Hib saccharide, the composition can include 20-40 ⁇ g of tetanus toxoid from the Hib conjugate, plus further tetanus toxoid as the 'T' antigen for protecting against C.tetani infection.
  • compositions and processes use a meningococcal conjugate from serogroup C. More preferred compositions and processes use separate meningococcal conjugates from both of serogroups A and C. These are preferably conjugated to a H.influenzae protein D carrier, but they may also be conjugated to a tetanus toxoid carrier, a diphtheria toxoid carrier or a CRMl 97 carrier. (2) Carrier/saccharide linkage in the Hih conjugate
  • the polysaccharide can first be activated using cyanogen bromide, then coupled to an adipic acid linker, and this linker-saccharide entity is then reacted with a carrier protein, and in particular with a tetanus toxoid carrier protein.
  • the first step involves cyanylation of a free -OH group on the Hib saccharide, illustrated as follows:
  • CNBr cyanogen bromide
  • CNBr is reacted with the saccharide under acidic conditions (typically pH 10 to 12).
  • acidic conditions typically pH 10 to 12.
  • cyanate esters are formed with the hydroxyl groups of the saccharide.
  • the high pH ionises the hydroxyl group to allow nucleophilic attack of the hydroxyl ion on the cyanate ion. Because of the high pH, various side reactions can occur, but only the cyanate ester formation is the topic of the invention.
  • adipic hydrazide spacer can be used. This can conveniently be achieved by using adipic acid dihydrazide (AADH):
  • the activated saccharide is then reacted with a tetanus toxoid carrier in the presence of EDAC ( 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide) :
  • EDAC will typically be used in the form of its hydrochloride salt:
  • EDAC permits the carboxyl group at the free end of the adipic acid linker to react with the carrier protein (typically with a free -SH, -NH 2 or -OH on an amino acid side chain), to form a conjugate that can be illustrated as follows, where -X- is -S-, -O- or -NH-, originating from the carrier:
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate is obtainable by a process comprising the steps of: (a) activating a Haemophilus influenzae type b capsular saccharide with cyanogen bromide, to give a cyanate ester;
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate of (v) includes a linker with one of the following two structures:
  • -X- is selected from the group consisting of: -O-, -S- or -NH-.
  • the carbamate is preferred.
  • the carrier protein for the Hib conjugate is preferably a tetanus toxoid.
  • compositions and processes use a meningococcal conjugate from serogroup C, and more preferred compositions and processes use separate meningococcal conjugates from both of serogroups A and C. These are preferably conjugated to a H.influenzae protein D carrier.
  • a mixture of Hib, MenA and MenC conjugates be used either for mixing with other vaccines or as a vaccine on its own.
  • the invention also provides a conjugate mixture comprising (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate is obtainable by a process comprising the steps of: (a) activating a Haemophilus influenzae type b capsular saccharide with cyanogen bromide, to give a cyanate ester; (b) adding an adipic hydrazide spacer to the cyanate ester, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein by
  • the invention also provides a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate of (i) includes a linker with one of the following two structures:
  • the Hib conjugate described above is linked to the carrier protein by a spacer.
  • Direct linkage has been found to be particularly suitable for meningococcal conjugates, especially where protein D is used as the carrier and where the Hib conjugate does not use direct linkage (to avoid the linkers from crossing any possible threshold at which they may become immunogenic).
  • a -OH group in the meningococcal saccharide is first cyanylated ⁇ e.g. as described above) to give a cyanate ester.
  • the -OCN group is then used to link directly to a side chain in the carrier, such as a free -NH 2 group, a free -SH group or a free -OH group. Linkage to a free -NH 2 in a lysine side chain is preferred.
  • the cyanylation reaction is preferably achieved using an organic cyanylating reagent, such as a l-cyano-4-(dimethylamino)-pyridinium reagent ('CDAP').
  • organic cyanylating reagent can be selected from the group consisting of l-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate, p-nitrophenylcyanate ('pNPC'), and N-cyanotriethyl-ammonium tetrafluoroborate ('CTEA').
  • the activation reaction can be carried out at neutral pH, which can help to retain the stability and integrity of the polysaccharide. In particular, it can help to retain -OAc groups (see below).
  • the cyanylating reagent is used at pH 6-8 in a non-nucleophilic buffer e.g. in saline, HEPES, phosphate, water and some organic solvents [6].
  • the CDAP can be dissolved in acetonitrile and added to an aqueous saccharide solution. After conjugation, the reaction can be quenched by the addition of glycine, which blocks any unreacted cyanate groups.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that the serogroup A conjugate is obtainable by a process comprising the steps of: (a) cyanylating a serogroup A capsular saccharide to give a cyanate ester; and (b) coupling the cyanate ester directly to a protein carrier.
  • the vaccine may also include (vii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein
  • the invention also provides a process for preparing a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup A conjugate is produced by a process comprising the steps of: (a) cyanylating a serogroup A capsular saccharide to give a cyanate ester; and (b) coupling the cyanate ester directly to a carrier protein.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup C conjugate is obtainable by a process comprising the steps of: (a) cyanylating a serogroup C capsular saccharide to give a cyanate ester; and (b) coupling the cyanate ester directly to a carrier protein.
  • the vaccine may also include (vii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein
  • the invention also provides a process for preparing a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup C conjugate is produced by a process comprising the steps of: (a) cyanylating a serogroup C capsular saccharide to give a cyanate ester; and (b) coupling the cyanate ester directly to a carrier protein.
  • the invention also provides vaccines and processes in which both serogroup A and serogroup C conjugates are prepared in this manner and are then combined.
  • a Hib conjugate can also be added, to give a conjugate mixture comprising all three of Hib, MenA and MenC. (4) O-acetylation of the serogroup C conjugate
  • meningococcal serogroup C capsular saccharide is an ⁇ 2 ⁇ 9-linked homopolymer of sialic acid (N-acetylneuraminic acid), typically with O-acetyl (OAc) groups at C-7 or C-8 residues:
  • MenC strains (-12% of invasive isolates) produce a polysaccharide that lacks this OAc group.
  • the presence or absence of OAc groups generates unique epitopes, and the specificity of antibody binding to the saccharide may affect its bactericidal activity against O-acetylated (OAc-) and de-O-acetylated (OAc+) strains [7-9].
  • OAc- O-acetylated
  • OAc+ de-O-acetylated strains [7-9].
  • Licensed MenC conjugate vaccines include both OAc- (NeisVac-CTM) and OAc+ (MenjugateTM & MeningitecTM) saccharides.
  • OAc+ or OAc- strains can be used.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that at least 50% of the sialic acid residues in the serogroup C capsular saccharide of (vi) are O-acetylated at the C-7 or C-8 position.
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup C capsular saccharide is from a OAc+ strain.
  • a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenza
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the sialic acid residues in the serogroup C capsular saccharide of (vii) are not O-acetylated.
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup C capsular saccharide is from a OAc- strain.
  • These vaccines may also include (vii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein.
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ("T'), (iii) cellular pertussis antigen (Tw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg component; (b) combining the H.inflmnzae and N. meningitidis conjugates to give a mixed conjugate component, where
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) cellular pertussis antigen (Tw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg component; (b) combining the H.influenzae and N. meningitidis conjugates to give a mixed conjugate component, wherein
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) cellular pertussis antigen ('Pw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg component; (b) combining the H.influenzae and N. meningitidis conjugates to give a mixed conjugate component, where
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) cellular pertussis antigen ('Pw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg component; (b) combining the H.influenzae and N. meningitidis conjugates to give a mixed conjugate component, where
  • the vaccines made by these processes may also include (vii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein.
  • the invention also provides a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the sialic acid residues in the MenC conjugate are not O-acetylated.
  • the invention also provides a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the MenC capsular saccharide is from a OAc- strain.
  • the invention also provides a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that at least 50% of the sialic acid residues in the MenC conjugate are 0-acetylated at the C-7 or C-8 position.
  • the invention also provides a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the MenC capsular saccharide is from a OAc+ strain.
  • the minimum percentage may be higher e.g. 60%, 70%, 80%, 90% or higher.
  • Preferred strains for production of serogroup C conjugates are OAc+ strains, preferably of serotype 16, preferably of serosubtype P1.7a,l.
  • C:16:P1.7a,l OAc+ strains are preferred.
  • meningococcal serogroup A capsular saccharide is a homopolymer of N-acetyl-mannosamine- phosphate linked ⁇ l ⁇ 6, with partial O-acetylation at the C-3 and C-4 positions:
  • Acetylation at the C-3 position can be as high as 70-95%.
  • Conditions used to purify the saccharide can result in de-O-acetylation (e.g. under basic conditions), but the invention seeks to retain OAc.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that at least 50% of the mannosamine residues in the serogroup A capsular saccharide are O-acetylated at the C-3 position.
  • the vaccine may also include (vii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) cellular pertussis antigen ('Pw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg
  • the vaccine made by this processes may also include (vii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein.
  • the invention also provides a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that at least 50% of the mannosamine residues in the serogroup A capsular saccharide are O-acetylated at the C-3 position.
  • the minimum percentage may be higher e.g. 60%, 70%, 80%, 90% or higher.
  • Hib-conjugate antigens are not cheap to produce, and various strategies to economise their use have been developed [10-12].
  • One approach has been to give two doses conjugates at doses lower than the standard lO ⁇ g/dose (typically fractions e.g. 1 A, 1 A, VA, etc.) [10,12].
  • Hib-conjugates were administered at 5 ⁇ g/dose or 3.33 ⁇ g/dose i.e. Vz or Vz or the normal dose.
  • reference 13 compares full-dose, half-dose and third-dose use of Hib-conjugate in combination with a DTwP vaccine and, although geometric mean concentrations of anti-PRP bodies were reduced in patients receiving combined DTP-Hib vaccines compared to separate administration of DTP and Hib, acceptable protective anti-Hib immune responses were seen in all cases.
  • Reference 14 uses a 10-fold dilution of Hib-conjugate dosage by reconstituting a single Hib dose with a ten-dose vial of DTwP.
  • Reference 2 discloses reconstitution of lyophilised Hib-conjugate at full dose, half-dose or quarter-dose using the TRITANREKTM DTwP-HBsAg vaccine.
  • meningococcal conjugates in combination vaccines.
  • an amount of between 8 ⁇ g and 12 ⁇ g (measured as saccharide) of the Hib and meningococcal conjugates has been selected. This amount can be present in a single unit dose, or can be present per millilitre of the vaccine.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the vaccine contains between 8 ⁇ g/ml and 12 ⁇ g/ml of the Haemophilus influenzae type b capsular saccharide. It is preferred to include meningococcal conjugates for both of serogroups A and C.
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that the vaccine contains between 8 ⁇ g/ml and 12 ⁇ g/ml of the meningococcal serogroup A capsular saccharide.
  • the vaccine preferably also includes (vii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein.
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the vaccine contains between 8 ⁇ g/ml and 12 ⁇ g/ml of the meningococcal serogroup C capsular saccharide.
  • the vaccine preferably also includes (vii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the vaccine contains between 8 ⁇ g and 12 ⁇ g of the Haemophilus influenzae type b capsular saccharide per unit dose. It is preferred to include meningococcal conjugates for both of serogroups A and C.
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that the vaccine contains between 8 ⁇ g and 12 ⁇ g of the meningococcal serogroup A capsular saccharide per unit dose.
  • the vaccine preferably also includes (vii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein.
  • the invention also provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a
  • Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein characterised in that the vaccine contains between 8 ⁇ g and 12 ⁇ g of the meningococcal serogroup C capsular saccharide per unit dose.
  • the vaccine preferably also includes (vii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein.
  • Preferred vaccines have a saccharide dose of between 8 ⁇ g and 12 ⁇ g (per millilitre or per unit dose) for all three of the Hib, MenA and MenC conjugates.
  • vaccines of the invention can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a Hib conjugate and at least one meningococcal conjugate.
  • the two components are preferably packaged separately, and thus in general the invention provides a kit comprising: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a Hib conjugate and at least one meningococcal conjugate.
  • This approach avoids the depolymerisation of conjugates that can occur during aqueous storage conditions, which is a particular problem for Hib and MenA conjugates, particularly when combined.
  • the two components (a) and (b) are packaged separately e.g. in separate vials.
  • the contents of the first vial (containing D-T-wP-HBsAg) are preferably aqueous, and the contents of the second vial (containing the conjugates) are preferably lyophilised, such that vaccines of the invention can be prepared by reconstituting the lyophilised component with the aqueous component.
  • the invention provides a process for preparing a vaccine composition of the invention, comprising the steps of (a) providing a first component comprising D, T, wP and HBsAg antigens in aqueous form; (b) providing a second component comprising Hib and meningococcal conjugates in lyophilised form; and (c) mixing the first and second components to give the vaccine.
  • the mixing step will typically take place at the time of use.
  • the invention also provides a process for preparing a kit of the invention, comprising the steps of: (a) obtaining or preparing a first component comprising D, T, wP and HBsAg antigens; (b) obtaining or preparing a second component comprising Hib and meningococcal conjugates; and (c) combining the two components in the form of a kit. More specifically, the invention provides:
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H. influenzae type b capsular saccharide conjugated to a carrier protein and at least one N.menmgitidis capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate has a weight excess of carrier to saccharide with a weight ratio of carrier to saccharide of between 2:1 and 4:1.
  • a process for preparing a kit of the invention comprising the steps of: (a) preparing a first component comprising D, T, wP and HBsAg antigens; (b) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and at least one N. meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate has a weight excess of carrier to saccharide with a weight ratio of carrier protein to saccharide of between 2:1 and 4:1; and (c) combining the two components in the form of a kit.
  • kits comprising (i) a first component comprising D, T, wP and HBsAg antigens; and (ii) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and at least one N.
  • meningitidis capsular saccharide conjugated to a carrier protein characterised in that the H.influenzae conjugate is obtainable by a process comprising the steps of: (a) activating a Haemophilus influenzae type b capsular saccharide with cyanogen bromide, to give a cyanate ester; (b) adding an adipic hydrazide spacer to the cyanate ester, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein by carbodiimide condensation.
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and at least one N. meningitidis capsular saccharide conjugated to a carrier protein, characterised in that the H.influenzae conjugate includes a linker with one of the following two structures:
  • -X- is selected from the group consisting of: -O-, -S- or -NH-.
  • a process for preparing a kit of the invention comprising the steps of: (i) preparing a first component comprising D, T, wP and HBsAg antigens; (ii) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and at least one N.
  • H.influenzae conjugate is obtainable by a process comprising the steps of: (a) activating a H.influenzae type b capsular saccharide with cyanogen bromide, to give a cyanate ester; (b) adding an adipic hydrazide spacer to the cyanate ester, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein by carbodiimide condensation.
  • a process for preparing a kit of the invention comprising the steps of: (a) preparing a first component comprising D 5 T, wP and HBsAg antigens; (b) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and at least one N. meningitidis capsular saccharide conjugated to a carrier protein; and (c) combining the two components in the form of a kit, characterised in that the H.influenzae conjugate includes a linker with one of the following two structures:
  • -X- is selected from the group consisting of: -O-, -S- or -NH-.
  • a process for preparing a kit of the invention comprising the steps of: (i) preparing a first component comprising D, T, wP and HBsAg antigens; (ii) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a
  • N. meningitidis serogroup A capsular saccharide conjugated to a carrier protein characterised in that the N. meningitidis serogroup A conjugate is obtainable by a process comprising the steps of: (a) cyanylating a serogroup A capsular saccharide to give a cyanate ester; and (b) coupling the cyanate ester directly to a carrier protein.
  • a process for preparing a kit of the invention comprising the steps of: (a) preparing a first component comprising D, T, wP and HBsAg antigens; (b) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a N. meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the N. meningitidis serogroup C conjugate is obtainable by a process comprising the steps of: (a) cyanylating a serogroup C capsular saccharide to give a cyanate ester; and (b) coupling the cyanate ester directly to a carrier protein.
  • a process for preparing a kit of the invention comprising the steps of: (i) preparing a first component comprising D, T, wP and HBsAg antigens; (ii) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a JV. meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that the JV.
  • meningitidis serogroup A conjugate is obtainable by a process comprising the steps of: (a) cyanylating a serogroup A capsular saccharide to give an cyanate ester; (b) reacting the cyanate ester with a bifunctional linker, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein.
  • a process for preparing a kit of the invention comprising the steps of: (i) preparing a first component comprising D, T, wP and HBsAg antigens; (ii) preparing a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a
  • N. meningitidis serogroup C capsular saccharide conjugated to a carrier protein characterised in that the N. meningitidis serogroup C conjugate is obtainable by a process comprising the steps of:
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a N. meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that at least 50% of the sialic acid residues in the N. meningitidis serogroup C conjugate are O-acetylated at the C-7 or C-8 position.
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a N. meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the sialic acid residues in the N .meningitidis serogroup C conjugate are not O-acetylated.
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a N. meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the N. meningitidis serogroup C capsular saccharide is from a OAc+ strain.
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a N. meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the N. meningitidis serogroup C capsular saccharide is from a OAc- strain.
  • kits comprising (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a H.influenzae type b capsular saccharide conjugated to a carrier protein and a N. meningitidis serogroup A capsular saccharide conjugated to a carrier protein, characterised in that at least 50% of the mannosamine residues in the serogroup A capsular saccharide are O-acetylated at the C-3 position.
  • a process for preparing a kit of the invention comprising the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a first kit component; and
  • the first component of a kit is preferably made by mixing a DTPw component with a HBsAg component.
  • the second component of a kit is preferably a trivalent conjugate component comprising: (1) a Haemophilus influenzae capsular saccharide conjugated to a carrier protein; (2) a Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein; and (3) a Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein.
  • Preferred heptavalent vaccines of the invention comprise the seven antigenic components D, T, Pw, HBsAg, Hib-X, MenA-X and MenC-X. Although these can in principle be mixed in any order, it is particularly preferred, as described above, to prepare a first component (with the D, T, Pw and HBsAg antigens) and a second component (with the Hib, MenA and MenC conjugates), and to combine these two components at the time of use.
  • the D-T-Pw-HBsAg component is prepared by mixing a D-T-Pw component with a HBsAg component.
  • This order of mixing i.e. adding HBsAg to an existing DTPw mixture, rather than adding HBsAg before any of the D, T or Pw antigens
  • This order of mixing has been found to be particularly useful for making combination vaccines, particularly where the individual components of the vaccine are adsorbed to aluminium salts. It is different from the order of mixing disclosed in reference 15, where a D-T-HBsAg mixture is initially made, with a Pw stock solution then being added. It is also different from the order of mixing in reference 16, where a Pw-HBsAg mixture is combined with a D-T mixture.
  • the invention provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) a cellular pertussis antigen ('Pw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein ('Hib-X'), (vi) a Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein ('MenA-X'), and (vii) a Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein ('MenC-X'), characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg
  • the trivalent D-T-Pw component preferably includes an aluminium phosphate adjuvant and/or an aluminium hydroxide adjuvant. Most preferably, it includes both an aluminium phosphate adjuvant and an aluminium hydroxide adjuvant.
  • the monovalent HBsAg component is preferably adsorbed to an aluminium phosphate adjuvant [17].
  • the D and T toxoids are preferably adsorbed to an aluminium hydroxide adjuvant.
  • the mixed conjugate component preferably comprises conjugates from Hib & Men A, Hib & MenC or Hib & MenA & MenC.
  • conjugate component is adsorbed to an aluminium salt [2], and more preferably the conjugate component does not include an aluminium salt.
  • Most preferred conjugate components are unadjuvanted. They may, however, contain sugars, such as lactose and/or sucrose.
  • the tetravalent D-T-Pw-HBsAg component is preferably in aqueous form, and the trivalent conjugate component is preferably in lyophilised form, for reconstitution by an aqueous D-T-Pw-HBsAg component in step (c).
  • the D-T-Pw and the HBsAg components are preferably both in aqueous form when mixed.
  • three conjugates can be mixed in any order e.g. adding all three together, or mixing two (e.g. MenA+MenC, MenA+Hib, MenC+Hib) and then adding the third.
  • vaccines of the invention typically include at least one aluminium salt adjuvant.
  • the vaccines can include both aluminium hydroxide and aluminium phosphate adjuvants.
  • the invention provides a kit comprising: (a) a first component comprising D, T, wP and HBsAg antigens, and comprising both an aluminium hydroxide and an aluminium phosphate adjuvant; and (b) a second component comprising (i) a H.influenzae type b capsular saccharide conjugated to a carrier protein and (ii) at least one N. meningitidis capsular saccharide conjugated to a carrier protein.
  • HBsAg is preferably adsorbed to an aluminium phosphate adjuvant.
  • the D and T toxoids are preferably adsorbed to an aluminium hydroxide adjuvant.
  • the first component is preferably made by mixing a DTPw component with a HBsAg component.
  • the DTPw component preferably includes both aluminium hydroxide and aluminium phosphate.
  • the HBsAg component preferably contains aluminium phosphate.
  • the second component preferably none of the conjugates is adsorbed to an aluminium salt, and more preferably the second component does not include an aluminium salt.
  • Most preferred second components are unadjuvanted. They may, however, contain sugars, such as lactose or, preferably, sucrose.
  • the first component is preferably in aqueous form, and the second component is preferably in lyophilised form. Thus the first component can be used to reconstitute the second component to give a vaccine of the invention.
  • the Hib conjugate described above is linked to the carrier protein by a spacer.
  • Spacers can also be used in the meningococcal conjugates, but direct linkage is preferred (see above).
  • spacers are used in combination with cyanylation, the general scheme is to prepare a cyanate ester as described above. The ester is then activated by reaction with one functional group of a bifunctional linker (preferably a homo-bifunctional linker), to leave the other functional groups remaining for linkage to the carrier.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a
  • Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein characterised in that the serogroup A conjugate of (vi) is obtainable by a process comprising the steps of: (a) cyanylating a serogroup A capsular saccharide to give an cyanate ester; (b) reacting the cyanate ester with a bifunctional linker, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein.
  • the vaccine may also include (vii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein,
  • the invention also provides a process for preparing a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup A conjugate is produced by a process comprising the steps of: (a) cyanylating a serogroup A capsular saccharide to give a cyanate ester; (b) reacting the cyanate ester with a bifunctional linker, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein.
  • the invention provides a combination vaccine comprising (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) cellular pertussis antigen, (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, and (vi) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup C conjugate of (vii) is obtainable by a process comprising the steps of: (a) cyanylating a serogroup C capsular saccharide to give an cyanate ester; (b) reacting the cyanate ester with a bifunctional linker, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein.
  • the vaccine may also include (vii) Neisseri
  • the invention also provides a process for preparing a conjugate mixture comprising (i) Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the serogroup C conjugate of (iii) is produced by a process comprising the steps of: (a) cyanylating a serogroup C capsular saccharide to give a cyanate ester; (b) reacting the cyanate ester with a bifunctional linker, to give an activated saccharide; and (c) coupling the activated saccharide to a carrier protein.
  • the invention also provides vaccines and processes in which both serogroup A and serogroup C conjugates are prepared in this manner and are then combined.
  • Any suitable bifunctional linker can be used, provided that it has one functional group for covalent attachment to the cyanylated meningococcal saccharide and one functional group for attaching to the carrier.
  • the two functional groups may be the same (i.e. a homobifunctional linker) or they may be different (i.e. a heterobifuctional linker), depending on the groups to which attachment is desired.
  • (11) Process for addition of a preservative
  • Vaccines typically contain preservatives in order to prevent dangerous microbial growth.
  • a combination vaccine formed by mixing various components then the skilled person must choose where and when to include the preservative.
  • different components contain different preservatives.
  • the invention provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), (ii) a tetanus toxoid ('T'), (iii) a cellular pertussis antigen (Tw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, and (vii) a mercurial preservative, characterised in that the process comprises the steps of: (a) combining a trivalent D-T
  • the first kit component can be prepared by mixing (i) a trivalent D-T-Pw component (ii) a HBsAg and (iii) a separate preservative, wherein the preservative of (iii) is not present (ii).
  • the mercurial preservative may be thiomersal (also known as thimerosal or merthiolate) or timerfonate.
  • the mixed conjugate component (and the second kit component) may or may not include the preservative. It preferably does not include the preservative.
  • the monovalent HBsAg component may or may not include the preservative. If a mercurial preservative has been used then a purified HBsAg may be subjected to dialysis (e.g. with cysteine) before being used to make the combination vaccine [18].
  • the mixed conjugate component preferably includes a Hib conjugate, a MenA conjugate and a MenC conjugate.
  • the invention also provides a process for preparing a combination vaccine that comprises (i) a diphtheria toxoid ('D'), ( ⁇ ) a tetanus toxoid ('T'), (in) a cellular pertussis antigen ('Pw'), (iv) a hepatitis B virus surface antigen ('HBsAg'), (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, and (vii) a 2-phenoxyethanol preservative, characterised in that the process comprises the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, to give a tetravalent D-T-Pw-HBsAg component, wherein the D-T-Pw component does not contain 2-phenoxyethanol; (b) combining
  • the invention provides a process for preparing a kit of the invention, comprising the steps of: (a) combining a trivalent D-T-Pw component with a monovalent HBsAg component, wherein the D-T-Pw component does not include a 2-phenoxyethanol preservative, to give a first kit component; and (b) combining a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein with at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, to give a second kit component.
  • the first kit component can be prepared by mixing (i) a trivalent D-T-Pw component (ii) a HBsAg and (iii) a separate 2-phenoxyethanol preservative, wherein the preservative of (iii) is not present (i).
  • the mixed conjugate component (and the second kit component) may or may not include 2-phenoxyethanol preservative. It preferably does not include the preservative.
  • the monovalent HBsAg component may or may not include 2-phenoxyethanol preservative.
  • Conjugation chemistry is not always precise or stoichiometric, and can produce side products that are not desirable in a final vaccine product.
  • the invention provides methods for assaying and/or removing these side products when preparing a mixed conjugate component.
  • This component can be used to make vaccines of the invention, or as a component of kits of the invention.
  • the invention provides a process for preparing a conjugate mixture that comprises (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) conjugating a Hib capsular saccharide to tetanus toxoid using EDAC, and then removing EDU; (b) conjugating a MenA capsular saccharide to a protein carrier using a CDAP reagent, and then removing DMAP; (c) conjugating a MenC capsular saccharide to a protein carrier using a CDAP reagent, and then removing DMAP; and (d) mixing the Hib conjugate from step (a), the MenA conjugate from step (b) and the Men
  • the conjugate mixture can be lyophilised e.g. to give a component for use in kits of the invention.
  • the pH of the trivalent component Prior to lyophilisation, can be reduced e.g. to within the range 6.0+0.5, or about 6.1.
  • 'EDAC is l-ethyl-3-(3-dimethylaminopropyl)carbodiimide, a water-soluble carbodiimide that has been used to crosslink biological substances that contain carboxylate acids and primary amines (see above). It will typically be used as the hydrochloride salt.
  • ⁇ DU' is N-ethyl-N'-(3-dimethylaminopropyl)urea, a soluble reaction product of EDAC coupling:
  • EDU and excess EDAC can both be removed after a conjugation reaction by washing with dilute acid or water. [19].
  • 'CDAP' reagents include the l-cyano-4-(dimethylamino)-pyridinium group and are used cyanylating reagents. They are preferably used as the tetrafluoroborate salt:
  • 'DMAP' is 4-dimethylamino-pyridin, a reaction product of CDAP cyanylation:
  • DMAP can be removed by gel filtration, gel permeation chromatography, etc.
  • a gel permeation chromatography column can be used to separate conjugates, unreacted carrier, unreacted saccharide unreacted CDAP, unreacted glycine and DMAP in a single run, to give purified conjugate.
  • the conjugation reactions may involve the use of linkers, etc., as described above ⁇ e.g. the use of an adipic hydrazide spacer for preparation of Hib-T).
  • the invention also provides a process for preparing a conjugate mixture that comprises (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) conjugating a Hib capsular saccharide to a carrier protein using EDAC; (b) conjugating a MenA capsular saccharide to a protein carrier using a CDAP reagent; (c) conjugating a MenC capsular saccharide to a protein carrier using a CDAP reagent; (d) mixing the Hib conjugate from step (a), the MenA conjugate from step (b) and the MenC conjugate from step (c) to give the conjugate mixture; and (e) removing EDU and/or DMAP
  • the invention also provides a process for preparing a conjugate mixture that comprises (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) coupling a Hib capsular saccharide to tetanus toxoid using EDAC, and then assaying EDU; (b) coupling a MenA capsular saccharide to a protein carrier using a CDAP reagent, and then assaying DMAP; and (c) coupling a MenC capsular saccharide to a protein carrier using a CDAP reagent, and then assaying DMAP.
  • the process will typically include the further step of: (d) mixing the Hib conjugate from step
  • the invention also provides a process for preparing a conjugate mixture that comprises (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) coupling a Hib capsular saccharide to tetanus toxoid using EDAC; (b) coupling a MenA capsular saccharide to a protein carrier using a CDAP reagent; and (c) coupling a MenC capsular saccharide to a protein carrier using a CDAP reagent; (d) mixing the Hib conjugate from step (a), the MenA conjugate from step (b) and the MenC conjugate from step (c) to give the conjugate mixture; and (e) as
  • the invention also provides a process for preparing a conjugate mixture that comprises (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (ii) Neisseria meningitidis serogroup A capsular saccharide conjugated to a carrier protein, and (iii) Neisseria meningitidis serogroup C capsular saccharide conjugated to a carrier protein, characterised in that the process comprises the steps of: (a) conjugating a Hib capsular saccharide to a carrier protein using EDAC; (b) conjugating a MenA capsular saccharide to a protein carrier using EDAC; (c) conjugating a MenC capsular saccharide to a protein carrier using EDAC; (d) mixing the Hib conjugate from step (a), the MenA conjugate from step (b) and the MenC conjugate from step (c) to give the conjugate mixture; and (e) removing EDU from the conjugate mixture.
  • the EDAC/EDU protocol is particularly suitable where tetanus toxoid is the carrier protein.
  • the CDAP/DMAP protocol is particularly suitable where protein D is the carrier protein.
  • Weight ratio of saccharide to carrier in the Hib conjugate is between 1 :2.5 and 1 :3.5
  • D, T, wP & HBsAg are kit component with Al hydroxide and phosphate adjuvants
  • Particularly preferred combinations include: a. (1) & (2) b. (1) & (2) & (6) c. (1) & (2) & (12) d. (1) & (2) & (6) & (12) e. (3) & (4) f. (3) & (5) g. (3) & (4) & (5) h. (3) & (4) & (6) i. (3) & (5) & (6) j. (3) & (4) & (5) & (6) k. (8) & (9)
  • Combinations e. and f. (and then g., h., i. & j.) is advantageous because, where CDAP is used, delicate acetyl groups on the meningococcal saccharides can be retained.
  • Combination k. is advantageous because the correct order of mixing adjuvants and antigens can be critical to adsorption, and thus to efficacy and to long term storage stability.
  • Combination 1. is advantageous because it minimises the need to add preservative at multiple stages during production.
  • Diphtheria is caused by Corynebacterium diphtheriae, a Gram-positive non-sporing aerobic bacterium. This organism expresses a prophage-encoded ADP-ribosylating exotoxin ('diphtheria toxin'), which can be treated ⁇ e.g. using formalin or formaldehyde) to give a toxoid that is no longer toxic but that remains antigenic and is able to stimulate the production of specific anti-toxin antibodies after injection. Diphtheria toxoids are disclosed in more detail in chapter 13 of reference 1. Preferred diphtheria toxoids are those prepared by formaldehyde treatment. The diphtheria toxoid can be obtained by growing C.
  • diphtheriae in growth medium e.g. Fenton medium, or Linggoud & Fenton medium
  • growth medium e.g. Fenton medium, or Linggoud & Fenton medium
  • bovine extract e.g. bovine extract
  • formaldehyde treatment e.g. formaldehyde treatment
  • ultrafiltration and precipitation e.g. formaldehyde treatment
  • the toxoided material may then be treated by a process comprising sterile filtration and/or dialysis.
  • the diphtheria toxoid is preferably adsorbed onto an aluminium hydroxide adjuvant.
  • the diphtheria toxoid component is substantially free from any mercurial preservatives.
  • IU international units
  • the NIBSC supplies the 'Diphtheria Toxoid Adsorbed Third International Standard 1999' [20,21], which contains 160 IU per ampoule.
  • the 'Lf unit (“flocculating units” or the “limes flocculating dose") is defined as the amount of toxoid which, when mixed with one International Unit of antitoxin, produces an optimally flocculating mixture [22].
  • the NIBSC supplies 'Diphtheria Toxoid, Plain 1 [23], which contains 300 LF per ampoule, and also supplies 'The 1st International Reference Reagent For Diphtheria Toxoid For Flocculation Test' [24] which contains 900 LF per ampoule.
  • bovine materials are used in the culture of C. diphtheriae, they should be obtained from sources that are free from bovine spongiform encephalopathy (BSE) or from other transmissible spongiform encaphalopathies (TSEs).
  • BSE bovine spongiform encephalopathy
  • TSEs transmissible spongiform encaphalopathies
  • the ratio of diphtheria toxoid to tetanus toxoid in vaccines of the invention is usually between 2:1 and 3:1 (measured in Lf units), preferably between 2.4:1 and 2.6:1, and is more preferably 2.5:1.
  • the amount of diphtheria toxoid in vaccines of the invention is typically at least 30 IU/dose.
  • the tetanus toxoid is typically at least 30 IU/dose.
  • Tetanus is caused by Clostridium tetani, a Gram-positive, spore-forming bacillus. This organism expresses an endopeptidase ('tetanus toxin'), which can be treated to give a toxoid that is no longer toxic but that remains antigenic and is able to stimulate the production of specific anti-toxin antibodies after injection. Tetanus toxoids are disclosed in more detail in chapter 27 of reference 1. Preferred tetanus toxoids are those prepared by formaldehyde treatment. The tetanus toxoid can be obtained by growing C. tetani in growth medium (e.g. a Latham medium derived from bovine casein), followed by formaldehyde treatment, ultrafiltration and precipitation. The material may then be treated by a process comprising sterile filtration and/or dialysis.
  • growth medium e.g. a Latham medium derived from bovine casein
  • the tetanus toxoid may be adsorbed onto an aluminium hydroxide adjuvant, but this is not necessary (e.g. adsorption of between 0-10% of the total tetanus toxoid can be used).
  • the tetanus toxoid component is substantially free from any mercurial preservatives.
  • Quantities of tetanus toxoid can be expressed in international units (IU).
  • IU international units
  • the NIBSC supplies the 'Tetanus Toxoid Adsorbed Third International Standard 2000' [25,26], which contains 469 IU per ampoule.
  • the 'LF unit (“flocculating units” or the "limes flocculating dose") is defined as the amount of toxoid which, when mixed with one International Unit of antitoxin, produces an optimally flocculating mixture [22].
  • the NIBSC supplies 'The 1st International Reference Reagent for Tetanus Toxoid For Flocculation Test' [27] which contains 1000 LF per ampoule.
  • bovine materials are used in the culture of C.tetani, they should be obtained from sources that are free from bovine spongiform encephalopathy (BSE) or from other transmissible spongiform encaphalopathies (TSEs).
  • BSE bovine spongiform encephalopathy
  • TSEs transmissible spongiform encaphalopathies
  • the ratio of tetanus toxoid to diphtheria toxoid in vaccines of the invention is usually between 1 :2 and 1:3 (measured in Lf units), preferably between 1:2.4 and 1:2.6, and is more preferably 1:2.5.
  • the amount of tetanus toxoid in vaccines of the invention is typically at least 60 IU/dose.
  • the cellular pertussis antigens in vaccines are either cellular (whole cell) or acellular.
  • the invention uses cellular pertussis antigens, in the form of inactivated B.pertussis cells. Preparation of cellular pertussis antigens is well documented [e.g. see chapter 21 of reference 1] e.g. it may be obtained by heat inactivation of phase I culture of B.pertussis.
  • the cellular pertussis antigen may be adsorbed onto or mixed with an aluminium phosphate adjuvant.
  • Quantities of wP antigens can be expressed in international units (IU).
  • IU international units
  • the NIBSC supplies the 'Third International Standard For Pertussis Vaccine' [28], which contains 46 IU per ampoule.
  • Each ampoule contains the freeze-dried residue of 2.0 ml aliquots of an aqueous solution which contained 10 litres of bacterial suspension (equivalent to 180 opacity units in terms of the U.S. Opacity Standard) diluted with eight litres of M/ 15 Sorensen's buffer pH 7.0.
  • the 'OU' unit (“opacity units") is also used (e.g. 4 OU may be about 1 IU).
  • the amount of wP antigen in vaccines of the invention is typically at least 4 IU/dose.
  • Hepatitis B virus is one of the known agents which causes viral hepatitis.
  • the HBV virion consists of an inner core surrounded by an outer protein coat or capsid.
  • the viral core contains the viral DNA genome.
  • the major component of the capsid is a protein known as HBV surface antigen or, more commonly, 'HBsAg', a 226-amino acids with a molecular weight of -24 kDa.
  • All existing hepatitis B vaccines contain HBsAg, and when this antigen is administered to a vaccinee it stimulates the production of anti-HBsAg antibodies which protect against HBV infection.
  • HBsAg can be made in two ways.
  • the first method involves purifying the antigen in particulate form from the plasma of chronic hepatitis B carriers, as large quantities of
  • HBsAg are synthesized in the liver and released into the blood stream during an HBV infection.
  • the second way involves expressing the protein by recombinant DNA methods.
  • HBsAg for use with the method of the invention may be prepared in either way, but it is preferred to use HBsAg which has been recombinantly expressed.
  • the HBsAg is prepared by expression in a yeast, such as a Saccharomyces (such as S.cerevisiae) or a Hanensula (such as H.polymorpha).
  • Yeast-expressed HBsAg will generally be non-glycosylated.
  • the HBsAg will generally be in the form of substantially-spherical particles (average diameter of about 20nm), including a lipid matrix comprising phospholipids.
  • Yeast-expressed HBsAg particles may include phosphatidylinositol, which is not found in natural HBV virions.
  • the particles may also include a non-toxic amount of LPS in order to stimulate the immune system [29].
  • the HBsAg is preferably from HBV subtype adw2.
  • HBsAg may be adsorbed to an aluminium hydroxide adjuvant in the final vaccine (as in the well-known ENGERIX-BTM product), or may remain unadsorbed, it will generally be adsorbed to an aluminium phosphate adjuvant prior to being used in the process of the invention [17]. Quantities of HBsAg are typically expressed in micrograms. A typical amount of HBsAg per vaccine dose is lO ⁇ g.
  • the H.influenzae type B antigen used in vaccines of the invention comprises a Hib capsular saccharide antigen.
  • Saccharide antigens from H.influenzae b are well known [e.g. chapter 14 of ref. I].
  • the Hib saccharide is conjugated to a carrier protein in order to enhance its immunogenicity, especially in children.
  • the preparation of Hib capsular saccharide is well documented [e.g. references 30 to 39].
  • the PRP-D product uses a diphtheria toxoid carrier protein, and this carrier can also be used according to the invention.
  • the HbOC product uses a CRM197 carrier protein, and this carrier can also be used according to the invention.
  • the PRP-OMP product uses an outer membrane protein complex from serogroup B meningococcus as the carrier, and this carrier can also be used according to the invention.
  • the PRP-T product uses a tetanus toxoid carrier protein, and this carrier can also be used according to the invention.
  • H.influenzae protein D (see below) can also be used as the carrier for the Hib conjugate.
  • Preferred Hib conjugates used according to the present invention use tetanus toxoid as the carrier protein, to give the product commonly referred to as 'PRP-T'. This is the conjugate present in the HIBERIXTM product.
  • the carrier protein in the Hib conjugate is preferably different from the carrier protein(s) in the meningococcal co ⁇ jugate(s), but the same carrier can be used in some embodiments.
  • the saccharide moiety of the conjugate may comprise full-length polyribosylribitol phosphate (PRP) as prepared from Hib bacteria, and/or it may comprise fragments of full-length PRP.
  • PRP polyribosylribitol phosphate
  • Conjugates with a saccharide ⁇ rotein ratio (w/w) of between 1:5 ⁇ i.e. excess protein) and 5:1 (i.e. excess saccharide) may be used e.g. ratios between 1:2 and 5:1 and ratios between 1:1.25 and 1:2.5.
  • the weight ratio of saccharide to carrier protein is between 1:2.5 and 1:3.5.
  • the weight ratio of saccharide to carrier protein in the conjugate may be between 1:0.3 and 1:2 [5].
  • Ignoring tetanus toxoid included as an antigen, unconjugated carrier is preferably no more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight.
  • Administration of the Hib antigen preferably results in an anti-PRP antibody concentration of >0.15 ⁇ g/ml, and more preferably >1 ⁇ g/ml. These are the standard acceptable response thresholds.
  • Amounts of Hib conjugates are generally given in terms of mass of saccharide (i.e. the dose of the conjugate (carrier + saccharide) as a whole is higher than the stated dose) in order to avoid variation due to choice of carrier.
  • a typical amount of Hib saccharide per vaccine dose is lO ⁇ g.
  • Hib conjugates may be lyophilised prior to their use according to the invention. Further components may also be added prior to freeze-drying e.g. as stabilizers. Preferred stabilizers for inclusion are lactose, sucrose and mannitol, as well as mixtures thereof e.g. lactose/sucrose mixtures, sucrose/mannitol mixtures, etc.
  • the final vaccine may thus contain lactose and/or sucrose. Using a sucrose/mannitol mixture can speed up the drying process.
  • the meningococcal antigens used in vaccines of the invention comprise capsular saccharide antigens conjugated to carrier proteins.
  • Saccharide antigens from N. meningitidis are well known: a bivalent vaccine ME ⁇ CEVAX ACTM and a tetravalent vaccine ME ⁇ CEVAX ACWYTM have been known for many years [40, 41].
  • conjugate vaccines against serogroup C have been approved for human use, and include ME ⁇ JUGATETM [42], ME ⁇ I ⁇ GITECTM and ⁇ EISVAC-CTM. Mixtures of conjugates from serogroups A+C are known [43, 44] and mixtures of conjugates from serogroups A+C+W135+Y have been reported [45-48].
  • the meningococcal saccharide(s) used in the products and processes of the invention can be from one or more of serogroups A, C, W135 and Y e.g. A+C, A+W135, A+Y, C+W135, C+Y, W135+Y, A+C+W135, A+C+Y, C+W135+Y, A+C+W135+Y. It is preferred to use at least the serogroup C saccharide, and preferably to use the saccharides from both of serogroups A and C.
  • the invention may use any suitable meningococcal conjugates, with any suitable linkage chemistry and any suitable spacers (except where specific details are given).
  • the MENJUGATETM and MENINGITECTM products use a CRM 197 carrier protein, and this carrier can also be used according to the invention.
  • the NEISV AC-CTM product uses a tetanus toxoid carrier protein, and this carrier can also be used according to the invention.
  • a particularly preferred carrier protein for the meningococcal conjugates is protein D from Haemophilus influenzae, which is not present in any existing approved conjugate vaccines. This protein is described in detail in references 49 & 50, and its use as a carrier protein in conjugates is described in reference 51.
  • protein D includes fragments of the native full-length protein, as disclosed in reference 51, and also fusion proteins comprising either full-length protein D or these fragments ⁇ e.g. a fusion of a fragment of influenza virus NSl protein and a fragment of protein D).
  • the fragments will retain the ability to convert a T-independent saccharide antigens into a T-dependent antigen when conjugated thereto.
  • Typical fragments will include at least the N-terminal 1/3 of protein D.
  • the protein can conveniently be expressed in E.coli [50], and this recombinant material is preferred for use with the invention [51].
  • conjugates are referred to as 'MenA-D' and 'MenC-D'.
  • separate meningococcal conjugates should use separate carrier proteins (cf. reference 52), but it is preferred that these separate carriers should be the same as each other e.g. all meningococcal conjugates in the composition should use a tetanus toxoid carrier, or all meningococcal conjugates in the composition should use a protein D carrier, etc.
  • the carrier protein(s) in the meningococcal conjugate(s) is/are preferably different from the carrier protein in the Hib conjugate, but the same carrier can be used in some embodiments.
  • the saccharide moiety of the conjugate may comprise full-length saccharides as prepared from meningococci, and/or it may comprise fragments of full-length saccharides.
  • Meningococcal conjugates with a saccharide :protein ratio (w/w) of between 1:10 ⁇ i.e. excess protein) and 10:1 ⁇ i.e. excess saccharide) may be used e.g. ratios between 1:5 and 5:1, between 1:2.5 and 2.5:1, or between 1:1.25 and 1.25:1.
  • SBA serum bactericidal assay
  • meningococcal conjugates Concentrations of meningococcal conjugates are generally given in terms of mass of saccharide (i.e. the dose of the conjugate (carrier + saccharide) as a whole is higher than the stated dose) in order to avoid variation due to choice of carrier.
  • a typical amount of each meningococcal saccharide per vaccine dose is about 5 ⁇ g or about lO ⁇ g.
  • Meningococcal conjugates may be lyophilised prior to their use according to the invention. Further components may also be added prior to freeze-drying e.g. as stabilizers. Preferred stabilizers for inclusion are lactose and/or sucrose. The final vaccine may thus contain lactose and/or sucrose.
  • Conjugate mixtures The invention provides conjugate mixtures and processes for their preparation. These typically comprise a mixture of (i) a Hib conjugate, (ii) a MenA conjugate and (iii) a MenC conjugate.
  • the conjugate mixtures can be used as vaccines themselves and also as components for mixing with other antigens to make combination vaccines.
  • the conjugate mixture can contain more than three conjugates, but it is preferably a trivalent conjugate mixture.
  • Pentavalent conjugate mixtures, further comprising conjugated capsular saccharides from meningococcal serogroups Wl 35 and Y can also be prepared.
  • the conjugate mixture is preferably in lyophilised form.
  • the conjugate mixture preferably comprises none of the following antigens: diphtheria toxoid; B.pertussis antigens; poliovirus antigens; HBsAg.
  • none of the conjugates is adsorbed to an aluminium salt [2], and more preferably does not include an aluminium salt.
  • Most preferred mixed conjugate components are unadjuvanted. They may, however, contain sugars, such as lactose or, preferably, sucrose.
  • vaccines of the invention will typically include at least one aluminium salt adjuvant.
  • the vaccines can include both aluminium hydroxide and aluminium phosphate adjuvants. Where both are included, the weight ratio of the two adjuvants is approximately 1:1 e.g. an aluminium hydroxide : aluminium phosphate ratio of about 1.58:1.6.
  • aluminium adjuvants are typically referred to either as “aluminium hydroxide” or as “aluminium phosphate” adjuvants, these are names of convenience, as neither is a precise description of the actual chemical compound which is present [e.g. see chapter 9 of reference 54].
  • the invention can use any of the "hydroxide” or "phosphate” adjuvants that are in general use as adjuvants.
  • aluminium hydroxide typically aluminium oxyhydroxide salts, which are usually at least partially crystalline.
  • Aluminium oxyhydroxide which can be represented by the formula AlO(OH)
  • AlO(OH) 3 aluminium hydroxide
  • IR infrared
  • the adjuvants known as "aluminium phosphate” are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Hydroxyphosphates generally have a PO 4 /AI molar ratio between 0.3 and 1.2. Hydroxyphosphates can be distinguished from strict AlPO 4 by the presence of hydroxyl groups. For example, an IR spectrum band at 3164cm "1 (e.g. when heated to 200 0 C) indicates the presence of structural hydroxyls [ch. 9 of ref. 54].
  • the adjuvants can take any suitable form (e.g. gel, crystalline, amorphous, etc.).
  • the PO 4 /A1 3+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95+0.1.
  • a typical adjuvant is amorphous aluminium hydroxyphosphate with PO 4 /A1 molar ratio between 0.84 and 0.92, included at 0.6mg Al 3 VmI.
  • the aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts.
  • the aluminium phosphate will generally be particulate. Typical diameters of the particles are in the range 0.5-20 ⁇ m (e.g. about 5-10 ⁇ m) after any antigen adsorption.
  • the aluminium phosphate is preferably used in the form of an aqueous solution to which antigens are added (NB: it is common to refer to aqueous aluminium phosphate as a "solution” although, on a strict physicochemical view, the salt is insoluble and forms a suspension). It is preferred to dilute the aluminium phosphate to the required concentration and to ensure a homogenous solution before the addition of the antigenic components.
  • the concentration of Al 3+ prior to addition of antigens is generally between 0 and 10 mg/ml.
  • a preferred concentration is between 2 and 6 mg/ml.
  • An aluminium phosphate solution used to prepare a vaccine of the invention may contain a buffer (e.g. a phosphate or a histidine buffer), but this is not necessary.
  • the aluminium phosphate solution is preferably sterile and pyrogen-free.
  • the aluminium phosphate solution may include free aqueous phosphate ions e.g. present at a concentration between 1.0 and 2OmM, preferably between 5 and 15 mM, and more preferably about 10 mM.
  • the aluminium phosphate solution may also comprise sodium chloride.
  • the concentration of sodium chloride is preferably in the range of 0.1 to 100 mg/ml (e.g. 0.5-50 mg/ml, 1-20 mg/ml, 2-10 mg/ml) and is more preferably about 3+1 mg/ml.
  • the presence of NaCl facilitates the correct measurement of pH prior to adsorption of antigens.
  • an antigen is described as being "adsorbed" to an adjuvant, it is preferred that at least 50% (by weight) of that antigen is adsorbed e.g. 50%, 60%, 70%, 80%, 90%, 95%, 98% or more.
  • the diphtheria toxoid and tetanus toxoid are both totally adsorbed i.e. none is detectable in supernatant. Total adsorption of HBsAg is also preferred.
  • the combination vaccines of the invention may include further components. These components may have various sources. For example, they may be present in one of the antigenic components that is mixed during the process of the invention or may be added during the process separately from the antigenic components.
  • a physiological salt such as a sodium salt.
  • Sodium chloride (NaCl) is preferred, which may be present in the final vaccine product at between 1 and 20 mg/ml.
  • the final vaccine product may be a suspension with a cloudy appearance. This appearance means that microbial contamination is not readily visible, and so the vaccine preferably contains an antimicrobial agent. This is particularly important when the vaccine is packaged in multidose containers.
  • Preferred antimicrobials for inclusion are 2-phenoxyethanol and thimerosal. It is preferred, however, not to use mercurial preservatives ⁇ e.g. thimerosal) during the process of the invention. However, the presence of trace amounts may be unavoidable if an antigen used during the process ⁇ e.g. HBsAg) has previously been treated with such a preservative.
  • the final vaccine product contains less than about 25 ng/ml mercury. More preferably, the final vaccine product contains no detectable thimerosal. This will generally be achieved by removing the mercurial preservative from an antigen preparation prior to its addition in the process of the invention or by avoiding the use of thimerosal during the preparation of individual antigenic components.
  • the final vaccine product may retain trace amounts of formaldehyde ⁇ e.g. less than lO ⁇ g/ml, preferably ⁇ 5 ⁇ g/ml). Free amino acids ⁇ e.g.
  • a further possible component of the final vaccine which originates in the antigen preparations arises from less-than-total purification of antigens. Small amounts of B. pertussis, C.diphtheriae, C.tetani and S.cerevisiae proteins and/or genomic DNA may therefore be present. To minimize the amounts of these residual components, antigen preparations are preferably treated to remove them prior to the antigens being used in the process of the invention. Where aluminium salts are present within the final vaccine, the total amount of aluminium, expressed in terms OfAl 3+ , is preferably ⁇ 2 mg/ml ⁇ e.g.
  • the process of the invention will be used to provide bulk combination vaccine which is suitable for packaging, and then for distribution and administration. Concentrations mentioned above are typically concentrations in final packaged vaccine, and so concentrations in bulk vaccine may be higher (e.g. to be reduced to final concentrations by dilution).
  • the process of the invention may therefore comprise the further step of packaging the vaccine into containers for use. Suitable containers include vials and disposable syringes (preferably sterile ones).
  • vials are preferably made of glass or of a plastic material.
  • the vial is preferably sterilized before vaccine is added to it.
  • vials can be sealed with a latex-free stopper.
  • the vial may include a single dose of vaccine, or it may include more than one dose (a 'multidose' vial) e.g. 10 doses.
  • a 'multidose' vial e.g. 10 doses.
  • each dose should be withdrawn with a sterile needle and syringe under strict aseptic conditions, taking care to avoid contaminating the vial contents.
  • Preferred vials are made of colorless glass.
  • the syringe will not normally have a needle attached to it, although a separate needle may be supplied with the syringe for assembly and use.
  • Safety needles are preferred.
  • 1-inch 23-gauge, 1-inch 25-gauge and 5/8-inch 25-gauge needles are typical.
  • Syringes may be provided with peel-off labels on which the lot number and expiration date of the contents may be printed, to facilitate record keeping.
  • the plunger in the syringe preferably has a stopper to prevent the plunger from being accidentally removed during aspiration.
  • the syringes may have a latex rubber cap and/or plunger. Disposable syringes contain a single dose of vaccine.
  • the syringe will generally have a tip cap to seal the tip prior to attachment of a needle, and the tip cap is preferably made of butyl rubber. If the syringe and needle are packaged separately then the needle is preferable fitted with a butyl rubber shield. Grey butyl rubber is preferred. Preferred syringes are those marketed under the trade name "Tip-Lok"TM.
  • a glass container e.g. a syringe or a vial
  • a container made from a borosilicate glass rather than from a soda lime glass.
  • conjugate antigens When contained separately, conjugate antigens will typically be freeze-dried (lyophilized) in a separate container, such that the packaged vaccine will contain at least two separate containers. Prior to administration to a patient, the freeze-dried material will be reconstituted and diluted with the liquid from the other container.
  • the conjugate container Prior to administration to a patient, the freeze-dried material will be reconstituted and diluted with the liquid from the other container.
  • the conjugate container will be a vial and the other container will contain a liquid within a vial or a pre-filled syringe.
  • the liquid contents of the second container will be transferred into the vial containing the freeze-dried conjugate antigen powder, thereby reconstituting the conjugate antigens for administration to a patient.
  • the container for lyophilised conjugates is preferably a vial which has a cap (e.g.
  • a Luer lock adapted such that a pre-filled syringe can be inserted into the cap, the contents of the syringe can be expelled into the vial to reconstitute the freeze-dried material therein, and the contents of the vial can be removed back into the syringe.
  • a needle can then be attached and the vaccine can be administered to a patient.
  • the cap is preferably located inside a seal or cover, such that the seal or cover has to be removed before the cap can be accessed.
  • the combination vaccine of the invention is preferably administered to patients in 0.5ml doses.
  • the process of the invention may therefore comprise the step of extracting and packaging a 0.5ml sample of the bulk vaccine into a container. For multidose situations, multiple dose amounts will be extracted and packaged together in a single container. Where a vaccine is presented as a kit with a lyophilised component then the final dose after reconstitution is preferably 0.5ml. References to 0.5ml doses herein should be taken to mean 0.5ml+0.05ml.
  • the container in which the vaccine is packaged will usually then be enclosed within a box for distribution e.g. inside a cardboard box, and the box will be labeled with details of the vaccine e.g. its trade name, a list of the antigens in the vaccine (e.g. 'Diphtheria, tetanus, inactivated whole cell pertussis and hepatitis B recombinant, adsorbed vaccine', etc.), the presentation container (e.g. 'Disposable Prefilled Tip-Lok Syringes' or '10 x 0.5 ml Single-Dose Vials'), its dose (e.g. 'each containing one 0.5ml dose'), warnings (e.g.
  • Each box might contain more than one packaged vaccine e.g. five or ten packaged vaccines (particularly for vials). If the vaccine is contained in a syringe then the package may show a picture of the syringe.
  • the vaccine may be packaged together (e.g. in the same box) with a leaflet including details of the vaccine e.g. instructions for administration, details of the antigens within the vaccine, etc.
  • the instructions may also contain warnings e.g. to keep a solution of adrenaline readily available in case of anaphylactic reaction following vaccination, etc.
  • the packaged vaccine materials are preferably sterile.
  • the packaged vaccine materials are preferably non-pyrogenic e.g. containing ⁇ 1 EU (endotoxin unit, a standard measure) per dose, and preferably ⁇ 0.1 EU per dose.
  • ⁇ 1 EU endotoxin unit, a standard measure
  • the packaged vaccine materials are preferably gluten free.
  • the pH of any aqueous packaged vaccine materials is preferably between 6 and 8 e.g. between 6.5 and 7.5.
  • the process of the invention may therefore include a step of adjusting the pH of the bulk vaccine prior to packaging.
  • Any aqueous material within the packaged vaccine is preferably a turbid white suspension.
  • the packaged vaccine is preferably stored at between 2°C and 8 0 C. It should not be frozen.
  • a typical dosage schedule for the vaccine, or order to have full efficacy will involve administering more than one dose in a primary immunization schedule.
  • a typical primary schedule will involve three doses, given at intervals of about 6 to 8 weeks, with the first dose being given to a child aged between 6 and 9 weeks of age.
  • a 3-dose primary schedule at 6, 10 and 14 weeks of age is preferred, and this may be followed up with a fourth dose at 18 months.
  • the vaccine may also be used to complete the primary immunization schedule of a different vaccine.
  • the invention provides a method for raising an immune response in a patient, comprising administering a composition of the invention to the patient.
  • the invention also provides a composition of the invention, for use in medicine.
  • the invention also provides the use of (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) a cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, in the manufacture of a medicament for immunising a patient.
  • the invention also provides the use of (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) a cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, in the manufacture of a medicament for immunising a patient, wherein the medicament is used to reconstitute a conjugate mixture.
  • the invention also provides the use of (i) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein and (ii) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, in the manufacture of a medicament for immunising a patient, wherein the medicament is lyophilised and is administered after reconstitution by an aqueous vaccine comprising at least one further antigen.
  • Preferred medicaments are vaccines.
  • Medicaments will generally be administered directly to a patient.
  • Direct delivery may be accomplished by parenteral injection ⁇ e.g. intravenously, subcutaneously, intraperitoneally, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, aural, pulmonary or other mucosal administration. In general, however, they are administered by intramuscular injection.
  • Preferred sites for injection are the anterolateral thigh or the deltoid muscle of the upper arm.
  • These uses, methods and medicaments are preferably for immunisation against the pathogens stated above.
  • the patient is preferably a human, and may be a child ⁇ e.g. a toddler or infant), a teenager or an adult, but will generally be a child.
  • Preferred patients are aged between 0-36 months e.g. between 0-24 months, between 0-12 months, or between 0-6 months.
  • Vaccines of the invention may be administered at substantially the same time as an oral polio vaccine, such as a trivalent oral polio vaccine e.g. containing Type 1 poliovirus, Type 2 poliovirus and Type 3 poliovirus.
  • a child receiving the vaccine of the invention for the first time may have previously received oral polio vaccine and/or Bacillus Calmette-Guerin (BCG) vaccine.
  • BCG Bacillus Calmette-Guerin
  • preferred patient groups for immunisation include, but are not limited to: (a) children who have previously received oral polio vaccine; (b) children who have previously received BCG vaccine; (c) children who have previously received both oral polio and BCG vaccine; (d) children in group (a), (b) or (c) who have not previously received any of D, T, Pw, HBsAg, Hib conjugates and at least one meningococcal conjugate; and (e) children who have previously received oral polio vaccine, BCG, D, T, Pw, HBsAg, Hib conjugate and at least one meningococcal conjugate.
  • These children may be in any of the age groups specified above e.g.
  • the invention provides the use of (i) a diphtheria toxoid, (ii) a tetanus toxoid, (iii) a cellular pertussis antigen, (iv) a hepatitis B virus surface antigen, (v) a Haemophilus influenzae type b capsular saccharide conjugated to a carrier protein, (vi) at least one Neisseria meningitidis capsular saccharide conjugated to a carrier protein, in the manufacture of a medicament for immunising a patient in one of said groups (a) to (e).
  • the vaccine of the invention contains an aluminium-based adjuvant, settling of components may occur during storage. The vaccine should therefore be shaken prior to administration to a patient. The shaken vaccine will be a turbid white suspension.
  • composition “comprising” can mean “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X + Y.
  • Figure 1 shows western blot results for HBsAg stability in a composition.
  • the lanes are: (1) Laemmli sample buffer (LSB); (2) MW markers; (3-5) l ⁇ g of three separate control HBsAg preparations; (6-8) supernatant of three separate pentavalent lots; (9-10) LSB.
  • the lanes are: (1) MW markers; (2-4) l ⁇ g of three separate control HBsAg preparations; (5-7) supernatant of three separate pentavalent lots, stored for 2 weeks at 2-8 0 C; (8-10) supernatant of three separate pentavalent lots, stored for 2 weeks at 36-38 0 C.
  • Figure 2 shows the variation of pH over time for a pentavalent composition.
  • Figure 3 shows western blot results for HBsAg stability in an octavalent composition.
  • lane 1 contains MW markers; lane 2 contains a HBsAg control at l ⁇ g/ml; lane 3 contains the supernatant of the octavalent composition.
  • lane 4 contains LSB; lane 5 contains the same control as lane 2; lane 6 contains a DOC/TCA extract.
  • Yeast-expressed HBsAg, diphtheria toxoid, tetanus toxoid and whole-cell pertussis antigens were added to a suspension of an aluminium salt adjuvant.
  • the pH of the mixture was adjusted, and then a Hib-CRM197 conjugate was added, such that it did not become adsorbed to the aluminium adjuvant.
  • This process gave a pentavalent vaccine with the following composition:
  • HPAEC-PAD analysis of free saccharide was also carried out after 6 months at 2-8°C.
  • the data were as follows:
  • FIG. 2A shows variation of pH in the pentavalent vaccine over 6 months for three lots stored at 2-8 0 C.
  • Figure 2B shows variation of pH over 4 weeks for three lots stored at 36-38 0 C.
  • pH was stable over 6 months, while under thermal stress conditions there was a slight drop of 0.1 pH unit after 2 weeks and a further slight drop after 4 weeks. Even so, all pH values remained within the accepted range of 6.0 - 7.0.
  • Osmolarity of all three pentavalent lots was between 312 and 315 mOsm/Kg, centrally within the accepted range of 240-360 mOsm/Kg for injectable vaccines.
  • Evaluation of the potency and immunogenicity of antigens is important in order to assess the efficacy of a combination vaccine.
  • the potency of Diphtheria, Tetanus and Pertussis antigens in the pentavalent vaccine was evaluated and the immunogenicity of both CRM-Hib and HBsAg was tested.
  • ELISA analysis was carried out to evaluate the level of specific antibodies after immunisation. Immunogenicity of HBsAg was performed using a mouse model and a different immunisation schedule with respect to that used for the HBV potency.
  • mice received the pentavalent vaccine by subcutaneous injection (0.5ml, diluted 1:4 in saline) at days 0 and 14. The mice were bled on day 21 and HBsAg-specific antibodies were assessed by ELISA using either (a) the "Enzygnost Anti-HBs II" test (Dade Behring) or (b) the "Ausab EIA” test (Abbott). These ELISA tests have different formats and different sensitivities to HBsAg. Geometric Mean Titre values are thus not comparable between the two tests. However, within the scope of each test the GMT values for the sera were optimal. Results were as follows:
  • Adsorption of HBsAg to the aluminium adjuvant is an important factor for vaccine immunogenicity, and this parameter was measured by immunoblot.
  • the immunoblot procedure followed was essentially as follows: a 1 ml volume of vaccine supernatant was DOC/TCA precipitated and denatured with LSB and then loaded on a 12% acrylamide SDS-PAGE; 1 ⁇ g of each lot of HBsAg was loaded as control; a goat anti-HBsAg antibody preparation was used as primary antibody (diluted 1 : 1000) and an anti-goat POD conjugate (diluted 1 :2500) was used as secondary antibody.
  • the positive controls used in Figure 1 contained 1 ⁇ g HBsAg. A single band corresponding to the S peptide (24kDa) was seen, plus a band characteristic of aggregates ( ⁇ 45kDa). Pre-S2 was not seen.
  • the octavalent vaccine was also tested for HBsAg adsorption in a similar way.
  • a 1 ml sample was centrifuged at 3500 rpm for 10 minutes. The supernatant was removed to a fresh tube and precipitated with DOC/TCA. The pellet was resuspended in 200 ⁇ l extraction buffer, boiled for 5 minutes and centrifuged at 1300 rpm for 10 minutes. 20 ⁇ l of this extract and the supernatant precipitated with DOC/TCA were loaded on 12% SDS-PAGE for Western-Blot.
  • Figure 3A shows the octavalent vaccine at time zero
  • Figure 3B shows the vaccine after 8 months of storage at 2-8 0 C.
  • the absence of any significant staining in lanes 3 & 6 of Figure 3B shows that HBsAg adsorption remains stable over this storage period.
  • a D-T-Pw component was prepared that includes diphtheria toxoid adsorbed to an aluminium hydroxide adjuvant, tetanus toxoid also adsorbed to an aluminium hydroxide adjuvant, and whole-cell pertussis antigens with aluminium phosphate. This component contains thimerosal, but contains no 2-phenoxyethanol.
  • HBsAg is expressed and purified from a recombinant S.cerevisiae. The purified protein is adsorbed onto an aluminium phosphate antigen [17].
  • Hib CONJUGATE COMPONENT Hib polysaccharide is prepared from Hib, strain 20752 and after activation with cyanogen bromide and derivatisation with an adipic hydrazide spacer is covalently coupled to a tetanus toxoid via carbodiimide condensation, at a saccharide xarrier weight ratio of about 1 :3. After the reaction involving EDAC, EDU levels are measured.
  • Capsular saccharide from serogroup A meningococcus is purified and covalently conjugated to H.influenzae protein D using the CDAP technique. After the reaction involving CDAP, residual DMAP content is measured, and retention of OAc groups at C-3 is confirmed. A conjugate using a tetanus toxoid carrier is also prepared, also by CDAP conjugation.
  • MenC CONJUGATE COMPONENT Capsular saccharide from an OAc+ serogroup C meningococcus is purified and covalently conjugated to H.influenzae protein D using the CDAP technique. After the reaction involving CDAP, residual DMAP content is measured. Conjugates are also prepared from an OAc- strain. A conjugate using a tetanus toxoid carrier is also prepared, also by CDAP conjugation.
  • the D-T-Pw component is mixed with the HBsAg component, and this tetravalent mixture is packaged in aqueous form into a stoppered vial.
  • the HBsAg level is lO ⁇ g/dose.
  • the three conjugates are mixed and lyophilised as described in reference 2.
  • the lyophilised powder is packaged in a stoppered vial.
  • Each conjugate is present at 5 ⁇ g/dose.
  • a mixture with double this dose of each conjugate is also prepared.
  • the conjugate mixture is adjuvant-free.
  • the two vials are packaged together in a box.
  • the aqueous D-T-Pw-HBsAg material is withdrawn into a syringe, and is introduced into the lyophilised conjugate vial. After the lyophilised material is reactivated, it is withdrawn back into the syringe, ready for administration to patients.
  • Infants are given a 3 -dose primary vaccination at 6, 10 and 14 weeks, administered by intramuscular injection.
  • 140 infants receive GSK's TRITANRIX-HepB/Hib vaccine.
  • the vaccine shows excellent immunogenicity.
  • NIBSC code 98/560.
  • NEBSC code DIFT.
  • NIBSC code 98/552.
  • NIBSC code TEFT.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP06727568A 2005-03-17 2006-03-16 Kombinationsvakzine mit ganzzelligem keuchhusten-antigen Revoked EP1858551B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10075177A EP2206515A1 (de) 2005-03-17 2006-03-16 Kombinationsvakzine mit ganzzelligem Keuchhusten-Antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505518.1A GB0505518D0 (en) 2005-03-17 2005-03-17 Combination vaccines with whole cell pertussis antigen
PCT/IB2006/001124 WO2006097851A2 (en) 2005-03-17 2006-03-16 Combination vaccines with whole cell pertussis antigen

Publications (2)

Publication Number Publication Date
EP1858551A2 true EP1858551A2 (de) 2007-11-28
EP1858551B1 EP1858551B1 (de) 2010-05-05

Family

ID=34531441

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06727568A Revoked EP1858551B1 (de) 2005-03-17 2006-03-16 Kombinationsvakzine mit ganzzelligem keuchhusten-antigen
EP10075177A Withdrawn EP2206515A1 (de) 2005-03-17 2006-03-16 Kombinationsvakzine mit ganzzelligem Keuchhusten-Antigen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10075177A Withdrawn EP2206515A1 (de) 2005-03-17 2006-03-16 Kombinationsvakzine mit ganzzelligem Keuchhusten-Antigen

Country Status (15)

Country Link
US (1) US8883166B2 (de)
EP (2) EP1858551B1 (de)
JP (3) JP5679631B2 (de)
CN (1) CN101184503A (de)
AT (1) ATE466594T1 (de)
AU (1) AU2006224246B2 (de)
BR (1) BRPI0609134A2 (de)
CA (1) CA2601676C (de)
DE (1) DE602006014098D1 (de)
GB (1) GB0505518D0 (de)
MX (1) MX2007011399A (de)
NZ (1) NZ562382A (de)
PT (1) PT1858551E (de)
RU (1) RU2420315C2 (de)
WO (1) WO2006097851A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8529908B2 (en) 2005-01-14 2013-09-10 Novartis Ag Meningococcal conjugate vaccination

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5637848B2 (ja) * 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
DK2833914T3 (en) * 2012-04-04 2019-03-11 Vaxform Llc ADMINISTRATIVE SYSTEM FOR ORAL VACCINE ADMINISTRATION
RU2542393C2 (ru) * 2013-05-06 2015-02-20 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" (ФБУН РостовНИИ микробиологии и паразитологии) СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТА КАПСУЛЬНОГО ПОЛИСАХАРИДА Haemophilus influenzae ТИП b (Hib) C АНТИГЕНАМИ ДЛЯ СОЗДАНИЯ ИММУНОБИОЛОГИЧЕСКИХ ПРЕПАРАТОВ
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
WO2020236973A1 (en) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
CN115996750A (zh) * 2020-04-21 2023-04-21 Kbio控股有限公司 通过病毒和抗原偶联形成的疫苗

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2129899C (en) * 1992-02-11 2011-01-04 James J. Mond Dual carrier immunogenic construct
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0835663B1 (de) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
CA2222455C (en) 1995-03-22 2013-05-28 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
BR9608612A (pt) 1995-06-07 1999-05-04 Smithkline Beecham Biolog Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
CA2303105A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US20030022304A1 (en) * 1998-03-25 2003-01-30 Smithkline Beecham Biologicals, S.A. Vaccine composition
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1296715E (pt) * 2000-06-29 2012-01-19 Smithkline Beecham Biolog Composição vacinal multivalente
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
EA006947B1 (ru) 2001-01-23 2006-06-30 Авентис Пастер Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
ES2649048T3 (es) * 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
US20030124139A1 (en) * 2002-11-20 2003-07-03 Irina Esikova Compositions and methods for stabilizing biological molecules upon lyophilization
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
PL1631264T5 (pl) * 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE506963T1 (de) * 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
WO2005032584A2 (en) * 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
WO2005099751A2 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
AU2005242409A1 (en) * 2004-05-19 2005-11-24 Alza Corporation Method and formulation for transdermal delivery of immunologically active agents
US7537766B2 (en) * 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
WO2007071786A2 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102802662A (zh) * 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006097851A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8529908B2 (en) 2005-01-14 2013-09-10 Novartis Ag Meningococcal conjugate vaccination

Also Published As

Publication number Publication date
EP1858551B1 (de) 2010-05-05
BRPI0609134A2 (pt) 2010-02-23
JP2008533125A (ja) 2008-08-21
MX2007011399A (es) 2008-03-11
CA2601676C (en) 2014-08-19
JP2015034178A (ja) 2015-02-19
GB0505518D0 (en) 2005-04-27
CN101184503A (zh) 2008-05-21
RU2007138492A (ru) 2009-04-27
CA2601676A1 (en) 2006-09-21
AU2006224246A1 (en) 2006-09-21
ATE466594T1 (de) 2010-05-15
AU2006224246B2 (en) 2010-12-23
PT1858551E (pt) 2010-08-11
US8883166B2 (en) 2014-11-11
WO2006097851A3 (en) 2006-11-09
EP2206515A1 (de) 2010-07-14
JP5679631B2 (ja) 2015-03-04
WO2006097851A2 (en) 2006-09-21
RU2420315C2 (ru) 2011-06-10
DE602006014098D1 (de) 2010-06-17
JP2013018792A (ja) 2013-01-31
NZ562382A (en) 2009-04-30
US20090214586A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
EP1858551B1 (de) Kombinationsvakzine mit ganzzelligem keuchhusten-antigen
EP2152302B1 (de) Formulierung eines impfstoffes gegen meningitis
US8444992B2 (en) Multiple vaccination including serogroup C meningococcus
JP2010529103A5 (de)
AU2009326044B2 (en) Mixing lyophilised meningococcal vaccines with non-Hib vaccines
CA2746579C (en) Mixing lyophilised meningococcal vaccines with d-t-pa vaccines
US20150125486A1 (en) Adjuvanted formulations of pediatric antigens
AU2012261764A1 (en) Multiple vaccination including serogroup C meningococcus
AU2012261763A1 (en) Multiple vaccination including serogroup C meningococcus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070919

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080211

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MANNUCCI, DONATELLA

Inventor name: CONTORNI, MARIO,NOVARTIS VACCINES AND DIAGNOSTICS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602006014098

Country of ref document: DE

Date of ref document: 20100617

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100802

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100505

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E008148

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100816

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100806

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: SANOFI PASTEUR, INC.

Effective date: 20110204

Opponent name: GLAXO SMITHKLINE BIOLOGICALS S.A.

Effective date: 20110204

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602006014098

Country of ref document: DE

Effective date: 20110204

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NOVARTIS AG

REG Reference to a national code

Ref country code: GB

Ref legal event code: S72Z

Free format text: CLAIM LODGED; PATENTS COURT ON 6 JULY 2011 (HC11CO2255)

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20110908 AND 20110914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110316

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120323

Year of fee payment: 7

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

REG Reference to a national code

Ref country code: GB

Ref legal event code: S72Z

Free format text: CLAIM FOR REVOCATION LODGED AT THE PATENTS COURT ON 6 JULY 2011. PROCEEDINGS STAYED BY CONSENT ORDER DATED 31 JULY 2012 UPON THE TERMS SET OUT IN THE SETTLEMENT AGREEMENT (HC11CO2255).

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20130314

Year of fee payment: 8

Ref country code: HU

Payment date: 20130222

Year of fee payment: 8

Ref country code: FR

Payment date: 20130325

Year of fee payment: 8

Ref country code: GB

Payment date: 20130313

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110316

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20130309

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 602006014098

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 602006014098

Country of ref document: DE

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20130226

Year of fee payment: 8

Ref country code: PT

Payment date: 20130312

Year of fee payment: 8

27W Patent revoked

Effective date: 20130614

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20130614

REG Reference to a national code

Ref country code: PT

Ref legal event code: MP4A

Effective date: 20130724

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20130312

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R107

Ref document number: 602006014098

Country of ref document: DE

Effective date: 20130912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100805

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 466594

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130614